Skip to content
DataLookout
Menu

Low-PRISMNCT06482489

Accurate Prostate Cancer Following Using Low-Field MRI (Low-PRISM)

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to May 31, 2027
    • Eligibility criteria expanded, about 17 words
    • Publications: details revised at 6 of 6 entries
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 1, 2024 to Nov 1, 2024
    • Study sites: 0 to 1
    v3
  3. Minor Study description revisedv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Evaluate the diagnostic accuracy of 0.55T MRI in detecting prostate suspicious lesions using the PI-RADS grading score, with the results of as the reference standard.
Timeframe: 9 months

Secondary (2)

Protocol optimization on healthy volunteers
Image quality on patients with metal implants

Arms and interventions

Healthy volunteers for protocol optimization

The commencement of the study involves the formulation of the 0.55T MRI protocol. For this purpose, a cohort of 23 male volunteers will undergo a 0.55T MRI. The objective is to achieve the same spatial resolution and coverage as observed at 3T.

Study of 0.55T Prostate MRI in Adult Men with Metal Implants.

The second phase of the research will be carried out to compare the MRI image quality between 0.55T and 3T MRI. The study will involve 20 adult men, who on 3T prostate MRI, have DWI reported as sub-diagnostic (PI-QUAL \< 3) due to the presence of metallic implant(s).

Evaluation of 0.55T Prostate MRI in Adult Men with Suspicious Lesions.

The third phase includes 31 patients whose 3T MRIs detected lesions classified as PI-RADS 4/5 and who are scheduled for targeted prostate biopsy.

Devices: Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).

Sites

1 site in 1 country

  • Lausanne University HospitalLausanne, Canton of Vaud, Switzerland